Sign in
CompletedPhase 2

Ketamine-enhanced Prolonged Exposure Therapy in PTSD

Key facts

Who runs it
VA Office of Research and Development
Where
Minneapolis, United StatesSee the site
Trial code
Status
Completed
Phase
Phase 2
People taking part
73 people enrolled
Started
9 Mar 2021
Ended
7 Oct 2025
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Ketamine
  • Midazolam
Record updated
11 August 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • male or female Veterans between the ages of 18 and 75 years
  • diagnosis of PTSD
  • ability to provide written informed consent

Who cannot take part

  • history of moderate/severe head injury
  • history of psychosis
  • severe substance and/or alcohol use disorder in the last 6 months
  • females who are currently pregnant or breastfeeding
  • current high risk for suicide
  • current episode of mania/hypomania

Where in United States

  • Minneapolis VA Health Care System, Minneapolis, MNMinneapolis, United States

About the trial

What the trial wants to find out

The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo to reduce symptoms of Posttraumatic Stress Disorder (PTSD) among Veteran receiving Prolonged Exposure Therapy.

The 2 groups in the trial

  • Ketamine and prolonged exposure (PE)Treatment being tested

    Single IV ketamine 0.5 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.

    Treatment: Ketamine

  • Midazolam and prolonged exposure (PE)Placebo, for comparison

    Single IV midazolam 0.045 mg/kg 24-72 hrs prior to PE session at week 1,2, and 3 followed by 7 additional PE sessions.

    Treatment: Midazolam

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Repeated Ketamine Treatment to Accelerate Efficacy of Prolonged Exposure in PTSD
Record updated
11 August 2026